Leukemia

In a session during the 2023 National Comprehensive Cancer Network Annual Conference, Deborah M. Stephens, DO, provided important updates to treatment recommendations for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and identified key factors for selecting frontline and subsequent therapies, including IGHV gene status, 17p deletion/TP53 mutation status, age, patient comorbidities, and resistance mutations. Read More ›

A head-to-head phase 3 clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) has found that zanubrutinib (Brukinsa), a next-generation Bruton tyrosine kinase (BTK) inhibitor, was more effective at preventing disease progression and is better tolerated than ibrutinib (Imbruvica), a first-generation BTK inhibitor that is the current standard of care for this population of patients. Read More ›

Single cord blood transplantation could be an effective treatment option for AML patients aged ≥60 years, but the risks for engraftment failure and early nonrelapse mortality should be considered. Read More ›

Treatment with enasidenib in newly diagnosed patients with IDH2^mut acute myeloid leukemia (AML) was associated with low early death and high complete response (CR)/CR with incomplete hematologic recovery rates, and yielded durable remissions. Read More ›

A proof-of-principle study confirmed the benefit of combining large cohorts of data from patients with AML using the HARMONY Alliance platform, thus demonstrating that such “big data” can help inform individualized therapy for optimal clinical outcomes. Read More ›

Data from a larger cohort of patients with AML suggest IDH inhibitors may be of particular interest in older adults and patients aged >60 years, based on co-occurring NPM1 and DNMT3A mutations. Read More ›

A post-hoc analysis of data from the BRIGHT AML 1003 study showed improved overall survival associated with attaining various blood count thresholds after 1 cycle of glasdegib + LDAC versus LDAC alone in patients with newly diagnosed AML. Read More ›

Venetoclax + FLAG-IDA was effective, elicited deep responses, and had an acceptable safety profile across multiple AML subgroups, representing an attractive option for adverse-risk newly diagnosed and relapsed/refractory AML patients, and as a bridge to allo-SCT. Read More ›

An analysis of outcomes for patients with treatment-naïve AML ineligible for intensive chemotherapy receiving either azacitidine or decitabine in the ASTRAL-1 study showed no significant differences in complete response (CR), overall CR, overall survival, or safety. Read More ›

he SAL-DaunoDouble trial interim analysis suggests that, in patients with acute myeloid leukemia (AML) who respond well to a first 7+3 induction cycle of cytarabine plus anthracycline, it may be possible to omit a second induction cycle if deemed high-risk. Read More ›